Robert H. Earhart

1.2k total citations
45 papers, 1.1k citations indexed

About

Robert H. Earhart is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert H. Earhart has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Robert H. Earhart's work include Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert H. Earhart is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert H. Earhart collaborates with scholars based in United States, Canada and Russia. Robert H. Earhart's co-authors include Jim M. Koeller, Kendra D. Tutsch, G L Neil, John G. Wagner, Donald J. Weidler, Ermelinda Sakmar, Douglass C. Tormey, Thomas E. Davis, Hugh L. Davis and Paul K. Wilkinson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Robert H. Earhart

45 papers receiving 995 citations

Peers

Countries citing papers authored by Robert H. Earhart

Since Specialization

Citations

This map shows the geographic impact of Robert H. Earhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Earhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Earhart more than expected).

Fields of papers citing papers by Robert H. Earhart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Earhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Earhart. The network helps show where Robert H. Earhart may publish in the future.

Co-authorship network of co-authors of Robert H. Earhart

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H. Earhart. A scholar is included among the top collaborators of Robert H. Earhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H. Earhart. Robert H. Earhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer 2000 ·Annals of Oncology ·Chandra P. Belani, Avi I. Einzig, Philip Bonomi, Thomas Dobbs, (unknown), Robert H. Earhart, (unknown), James D. Luketich	42
2	A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. 1998 ·Journal of Clinical Oncology ·Vicente Valero, Stephen E. Jones, Daniel D. Von Hoff, Daniel J. Booser, Robert Mennel, Peter M. Ravdin, Frankie A. Holmes, Zaid Abdel Rahman, (unknown), John K. Erban, (unknown), Robert H. Earhart, Gabriel N. Hortobágyi, Howard A. Burris	188
3	Phase I study with the DNA sequence-specific agent adozelesin 1997 ·Anti-Cancer Drugs ·Howard A. Burris, Véronique Dièras, Mehmet Tunca, Robert H. Earhart, John R. Eckardt, Gladys Rodriguez, (unknown), (unknown), Elizabeth Campbell, Larry J. Schaaf, (unknown), Daniel D. Von Hoff	22
4	Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks 1995 ·Investigational New Drugs ·Brenda J. Foster, Patricia LoRusso, Elizabeth Poplin, Mark M. Zalupski, Manuel Valdivieso, Antoinette Wozniak, Lawrence E. Flaherty, (unknown), Robert H. Earhart, Laurence H. Baker	21
5	Phase I study of adozelesin (U-73,975) in patients with solid tumors 1994 ·Anti-Cancer Drugs ·(unknown), David S. Alberts, (unknown), (unknown), (unknown), (unknown), Gary Elfring, Robert H. Earhart	21
6	Phase I Study of Adozelesin Administered by 24-Hour Continuous Intravenous Infusion 1994 ·JNCI Journal of the National Cancer Institute ·Gini F. Fleming, Mark J. Ratain, Sean M. O’Brien, Richard L. Schilsky, P. C. Hoffman, (unknown), N. Vogelzang, (unknown), Robert H. Earhart	33
7	Human autopsy-tissue distribution of menogaril and its metabolites 1993 ·Cancer Chemotherapy and Pharmacology ·David J. Stewart, Darshan S. Grewaal, (unknown), Rakesh Goel, Nadia Z. Mikhael, (unknown), (unknown), Robert H. Earhart	5
8	A phase I clinical and pharmacokinetic study of the oral and the oral/ intravenous administration of menogaril 1993 ·Investigational New Drugs ·Geoffrey R. Weiss, Thomas D. Brown, (unknown), Daniel D. Von Hoff, Robert H. Earhart, Wade J. Adams, (unknown), (unknown), (unknown)	5
9	Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults 1992 ·Journal of Neuro-Oncology ·DavidJ. Stewart, Herman Hugenholtz, (unknown), (unknown), (unknown), Shailendra Verma, Robert H. Earhart, (unknown)	7
10	Short report: Phase I study of oral menogaril administered daily for 14 consecutive days 1992 ·Annals of Oncology ·David J. Stewart, (unknown), Savita Verma, Jean A. Maroun, (unknown), (unknown), (unknown), Robert H. Earhart	2
11	Phase 1 Trial of Oral Bropirimine in Superficial Bladder Cancer 1992 ·The Journal of Urology ·Michael F. Sarosdy, Donald L. Lamm, Richard D. Williams, Timothy D. Moon, Robert C. Flanigan, E. David Crawford, N. E. Wilks, Robert H. Earhart, James A. Merritt	40
12	A phase II study of menogaril (NSC-269148) in colorectal carcinoma 1990 ·Investigational New Drugs ·Robert P. Whitehead, Robert H. Earhart, Thomas R. Fleming, Phyllis J. Goodman, John S. Macdonald, (unknown), (unknown)	1
13	Phase I study of oral menogaril administered on a once weekly schedule 1990 ·Investigational New Drugs ·David J. Stewart, Shailendra Verma, Jean A. Maroun, (unknown), Robert H. Earhart	9
14	Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas 1990 ·Investigational New Drugs ·Robert H. Earhart, (unknown), Alex Y. Chang, Ernest C. Borden, Masanori Shiraki, (unknown), Robert L. Comis, Thomas E. Davis, Thomas J. Smith	54
15	Phase I Study of Weekly Intravenous Administration of Menogaril to Adults with Solid Tumors 1989 ·American Journal of Clinical Oncology ·David J. Stewart, Jean A. Maroun, Shailendra Verma, D Perrault, Robert H. Earhart	8
16	Phase II trial of continuous drug infusions in advanced ovarian carcinoma: Acivicin versus vinblastine 1989 ·Investigational New Drugs ·Robert H. Earhart, Janardan D. Khandekar, David Faraggi, Roger Schinella, Thomas E. Davis	8
17	Analgesia with oral narcotics and added ibuprofen in cancer patients. 1985 ·PubMed ·(unknown), Christine A. Sorkness, Robert H. Earhart	22
18	Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. 1983 ·PubMed ·Robert H. Earhart, Patricia Martín, Kendra D. Tutsch, Erdoğan Ertürk, Richard H. Wheeler, (unknown)	58
19	Phase II study of PALA and AMSA in advanced renal cell carcinoma 1983 ·American Journal of Clinical Oncology ·Robert H. Earhart, Paul Elson, Susan N. Rosenthal, Richard G. Hahn, Robert E. Slayton	10
20	Comparative bioavailability: Eight commercial prednisone tablets 1976 ·Journal of Pharmacokinetics and Biopharmaceutics ·Timothy J. Sullivan, (unknown), Ermelinda Sakmar, Donald J. Weidler, Robert H. Earhart, John G. Wagner	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact